Studies show that users can achieve up to 15% body weight reduction over 68 weeks
Studies on long-term semaglutide use (Wegovy) Wegovy is the higher-strength version of semaglutide that is FDA-approved for weight loss
Over the year after withdrawal, participants regained about two thirds of prior weight loss, and improvements in blood pressure, lipids, and glycaemic markers tended to revert toward baseline
For inflammation Chronic low-grade inflammation, sometimes called inflammaging, contributes to fatigue, joint pain, insulin resistance, and cognitive changes
These changes are particularly notable in women with pre-existing hormonal conditions such as polycystic ovary syndrome (PCOS), where weight loss can actually restore ovulatory function
Because it bypasses insurance and PBMs, it functions as a cash-pay pharmacy